State Street Corp Reduces Stock Position in Astria Therapeutics, Inc. (NASDAQ:ATXS)

State Street Corp cut its holdings in Astria Therapeutics, Inc. (NASDAQ:ATXS) by 24.1% in the 3rd quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 1,556,283 shares of the biotechnology company’s stock after selling 495,436 shares during the period. State Street Corp owned 2.76% of Astria Therapeutics worth $17,135,000 as of its most recent SEC filing.

A number of other hedge funds have also bought and sold shares of ATXS. RA Capital Management L.P. increased its holdings in shares of Astria Therapeutics by 1.2% in the third quarter. RA Capital Management L.P. now owns 5,105,213 shares of the biotechnology company’s stock worth $56,208,000 after purchasing an additional 61,457 shares during the period. Redmile Group LLC purchased a new position in Astria Therapeutics during the third quarter worth about $3,423,000. Patient Square Capital LP bought a new position in shares of Astria Therapeutics in the third quarter worth approximately $434,000. PDT Partners LLC bought a new stake in Astria Therapeutics during the third quarter valued at approximately $140,000. Finally, Vestal Point Capital LP grew its stake in Astria Therapeutics by 23.1% in the 3rd quarter. Vestal Point Capital LP now owns 4,000,000 shares of the biotechnology company’s stock worth $44,040,000 after buying an additional 750,000 shares in the last quarter. 98.98% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

A number of research firms have recently issued reports on ATXS. HC Wainwright reaffirmed a “buy” rating and set a $16.00 price objective on shares of Astria Therapeutics in a report on Tuesday, December 10th. Oppenheimer raised their price objective on Astria Therapeutics from $26.00 to $28.00 and gave the company an “outperform” rating in a report on Thursday, November 14th. Five equities research analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat.com, the stock presently has an average rating of “Buy” and a consensus price target of $25.60.

Astria Therapeutics Stock Up 0.2 %

NASDAQ:ATXS opened at $9.54 on Wednesday. The firm has a market capitalization of $538.38 million, a P/E ratio of -4.56 and a beta of 0.67. Astria Therapeutics, Inc. has a 52 week low of $6.58 and a 52 week high of $16.90. The company has a fifty day moving average of $10.58 and a 200 day moving average of $10.73.

About Astria Therapeutics

Astria Therapeutics, Inc, a biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics for allergic and immunological diseases in the United States. Its lead product candidate is STAR-0215, a monoclonal antibody inhibitor of plasma kallikrein, which is in Phase 1b/2 clinical trials for the treatment of hereditary angioedema.